Tyson Anderson
Primary Care · Washington, DCNPI 1619427390
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Gilead accounts for 85.3% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $14,738, more than ten times the $18 reported in 2021. Among primary care clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $111.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$16K
- Viiv Healthcare Company$1K
- Theratechnologies Inc.$486
- AbbVie$191
- Lundbeck LLC$131
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$93
- plus $469 from 9 others
What the payments were for
- Consulting fees$2,29012%
- Speaking & faculty fees$9,00349%
- Travel & lodging$1,5989%
- Food & beverage$5,48130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 74 | $15,663 |
| Viiv Healthcare Company | 39 | $1,340 |
| Theratechnologies Inc. | 13 | $486 |
| AbbVie | 10 | $191 |
| Lundbeck LLC | 5 | $131 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $93 |
| Merck | 4 | $83 |
| Otsuka America Pharmaceutical, Inc. | 3 | $76 |
| Novo Nordisk | 3 | $72 |
| Pfizer | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| Lilly USA, LLC | 2 | $53 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Tolmar, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,372 in reported general payments places this provider in the 95th percentile of 21 primary care providers in District of Columbia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $48,315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $15,663 | $48,31512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 primary care providers in District of Columbia.
Other primary care in Washington
- Jessicamarie Fox-BartlettWashington$5K
- Michaela BradyWashington$1K
- Yelena BurshteynWashington$791
- Jasmine BurgeWashington$509
- Jared WoodingsWashington$279
- Meredith HaaseWashington$270
- Maryam Mohammad ZadehWashington$235
- Natalie KekuhWashington$154
- Robin BoydWashington$146
- Tiffany NewtonWashington$135
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.